Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases

• Main Authors: Andrea Gila-Diaz, Gloria Herranz Carrillo, Pratibha Singh, David Ramiro-Cortijo
• Format: Article
• Language: English
• Published: MDPI AG 2021-06-01
• Series: Antioxidants
• Subjects: oxylipins; specialized pro-resolving mediators; long chain polyunsaturated fatty acids; newborn; premature infant; cardiovascular diseases
• Online Access: https://www.mdpi.com/2076-3921/10/6/933

Cardiovascular disease remains a leading cause of mortality worldwide. Unresolved inflammation plays a critical role in cardiovascular diseases development. Specialized Pro-Resolving Mediators (SPMs), derived from long chain polyunsaturated fatty acids (LCPUFAs), enhances the host defense, by resolving the inflammation and tissue repair. In addition, SPMs also have anti-inflammatory properties. These physiological effects depend on the availability of LCPUFAs precursors and cellular metabolic balance. Most of the studies have focused on the impact of SPMs in adult cardiovascular health and diseases. In this review, we discuss LCPUFAs metabolism, SPMs, and their potential effect on cardiovascular health and diseases primarily focusing in neonates. A better understanding of the role of these SPMs in cardiovascular health and diseases in neonates could lead to the development of novel therapeutic approaches in cardiovascular dysfunction.